Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 15054-

  Guo, Xi zhi J ^a,b   Dash, Pradyot ^a   Calverley, Matthew ^a   Tomchuck, Suzanne ^a   Dallas, Mari H ^a   Thomas, Paul G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHABETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMADELTA CHAIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; T LYMPHOCYTE RECEPTOR ALPHA BETA CHAIN;

ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN CELL; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; DNA LIBRARY; JURKAT CELL LINE; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PROTEIN ANALYSIS; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

EID: 84968872488     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.54     Document Type: Article

References (65)

1. 1 Restifo, NP, Dudley, ME, Rosenberg, SA, Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12 (2012), 269–281.
2. 2 Rosenberg, SA, Restifo, NP, Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
3. 3 Wherry, EJ, Ha, SJ, Kaech, SM, Haining, WN, Sarkar, S, Kalia, V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
4. 4 Baitsch, L, Baumgaertner, P, Devêvre, E, Raghav, SK, Legat, A, Barba, L, et al. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest 121 (2011), 2350–2360.
5. 5 Wherry, EJ, Kurachi, M, Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15 (2015), 486–499.
6. 6 Besser, MJ, Shapira-Frommer, R, Itzhaki, O, Treves, AJ, Zippel, DB, Levy, D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19 (2013), 4792–4800.
7. 7 Klaver, Y, Kunert, A, Sleijfer, S, Debets, R, Lamers, CH, Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy 7 (2015), 513–533.
8. 8 Lamers, CH, Willemsen, R, van Elzakker, P, van Steenbergen-Langeveld, S, Broertjes, M, Oosterwijk-Wakka, J, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117 (2011), 72–82.
9. 9 Chapuis, AG, Thompson, JA, Margolin, KA, Rodmyre, R, Lai, IP, Dowdy, K, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 109 (2012), 4592–4597.
10. 10 Han, EQ, Li, XL, Wang, CR, Li, TF, Han, SY, Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol, 6, 2013, 47.
11. 11 Hinrichs, CS, Borman, ZA, Cassard, L, Gattinoni, L, Spolski, R, Yu, Z, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 106 (2009), 17469–17474.
12. 12 Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:20 Pt 1 (2006), 6106–6115.
13. 13 Ramos, CA, Dotti, G, Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 11 (2011), 855–873.
14. 14 Varela-Rohena, A, Carpenito, C, Perez, EE, Richardson, M, Parry, RV, Milone, M, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res 42 (2008), 166–181.
15. 15 Schmitt, TM, Ragnarsson, GB, Greenberg, PD, T cell receptor gene therapy for cancer. Hum Gene Ther 20 (2009), 1240–1248.
16. 16 Stauss, HJ, Morris, EC, Abken, H, Cancer gene therapy with T cell receptors and chimeric antigen receptors. Curr Opin Pharmacol 24 (2015), 113–118.
17. 17 Schmitt, TM, Stromnes, IM, Chapuis, AG, Greenberg, PD, New strategies in engineering T-cell receptor gene-modified T cells to more effectively target malignancies. Clin Cancer Res 21 (2015), 5191–5197.
18. 18 Vavassori, S, Kumar, A, Wan, GS, Ramanjaneyulu, GS, Cavallari, M, El Daker, S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 14 (2013), 908–916.
19. 19 Birnbaum, ME, Mendoza, JL, Sethi, DK, Dong, S, Glanville, J, Dobbins, J, et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157 (2014), 1073–1087.
20. 20 Luoma, AM, Castro, CD, Mayassi, T, Bembinster, LA, Bai, L, Picard, D, et al. Crystal structure of Vδ1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells. Immunity 39 (2013), 1032–1042.
21. 21 Linnemann, C, Heemskerk, B, Kvistborg, P, Kluin, RJ, Bolotin, DA, Chen, X, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med 19 (2013), 1534–1541.
22. 22 Kobayashi, E, Mizukoshi, E, Kishi, H, Ozawa, T, Hamana, H, Nagai, T, et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med 19 (2013), 1542–1546.
23. 23 Howie, B, Sherwood, AM, Berkebile, AD, Berka, J, Emerson, RO, Williamson, DW, et al. High-throughput pairing of T cell receptor α and β sequences. Sci Transl Med, 7, 2015, 301ra131.
24. 24 Perko, R, Kang, G, Sunkara, A, Leung, W, Thomas, PG, Dallas, MH, Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol Blood Marrow Transplant 21 (2015), 130–136.
25. 25 Silva-Santos, B, Serre, K, Norell, H, γδ T cells in cancer. Nat Rev Immunol 15 (2015), 683–691.
26. 26 Dash, P, McClaren, JL, Oguin, TH 3rd, Rothwell, W, Todd, B, Morris, MY, et al. Paired analysis of TCRα and TCRβ chains at the single-cell level in mice. J Clin Invest 121 (2011), 288–295.
27. 27 Wang, GC, Dash, P, McCullers, JA, Doherty, PC, Thomas, PG, T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med, 4, 2012, 128ra42.
28. 28 Bryksin, AV, Matsumura, I, Overlap extension PCR cloning: a simple and reliable way to create recombinant plasmids. Biotechniques 48 (2010), 463–465.
29. 29 Uldrich, AP, Le Nours, J, Pellicci, DG, Gherardin, NA, McPherson, KG, Lim, RT, et al. CD1d-lipid antigen recognition by the γδ TCR. Nat Immunol 14 (2013), 1137–1145.
30. 30 Yoshio Ogawa, MN, Gamma-delta T cells may function as carrier vehicles in adenovirus vector-based gene therapy. J Cancer Sci Ther 5 (2013), 384–390.
31. 31 Holst, J, Szymczak-Workman, AL, Vignali, KM, Burton, AR, Workman, CJ, Vignali, DA, Generation of T-cell receptor retrogenic mice. Nat Protoc 1 (2006), 406–417.
32. 32 Bettini, ML, Bettini, M, Nakayama, M, Guy, CS, Vignali, DA, Generation of T cell receptor-retrogenic mice: improved retroviral-mediated stem cell gene transfer. Nat Protoc 8 (2013), 1837–1840.
33. 33 Sharma, P, Yan, F, Doronina, VA, Escuin-Ordinas, H, Ryan, MD, Brown, JD, 2A peptides provide distinct solutions to driving stop-carry on translational recoding. Nucleic Acids Res 40 (2012), 3143–3151.
34. 34 Szymczak, AL, Workman, CJ, Wang, Y, Vignali, KM, Dilioglou, S, Vanin, EF, et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22 (2004), 589–594.
35. 35 Bettini, ML, Bettini, M, Vignali, DA, T-cell receptor retrogenic mice: a rapid, flexible alternative to T-cell receptor transgenic mice. Immunology 136 (2012), 265–272.
36. 36 Day, EB, Guillonneau, C, Gras, S, La Gruta, NL, Vignali, DA, Doherty, PC, et al. Structural basis for enabling T-cell receptor diversity within biased virus-specific CD8+ T-cell responses. Proc Natl Acad Sci USA 108 (2011), 9536–9541.
37. 37 Bartok, I, Holland, SJ, Kessels, HW, Silk, JD, Alkhinji, M, Dyson, J, T cell receptor CDR3 loops influence alphabeta pairing. Mol Immunol 47 (2010), 1613–1618.
38. 38 Siegers, GM, Swamy, M, Fernández-Malavé, E, Minguet, S, Rathmann, S, Guardo, AC, et al. Different composition of the human and the mouse gammadelta T cell receptor explains different phenotypes of CD3gamma and CD3delta immunodeficiencies. J Exp Med 204 (2007), 2537–2544.
39. 39 Moran, AE, Holzapfel, KL, Xing, Y, Cunningham, NR, Maltzman, JS, Punt, J, et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 208 (2011), 1279–1289.
40. 40 Gao, P, Han, X, Zhang, Q, Yang, Z, Fuss, IJ, Myers, TG, et al. Dynamic changes in E-protein activity regulate T reg cell development. J Exp Med 211 (2014), 2651–2668.
41. 41 Au-Yeung, BB, Zikherman, J, Mueller, JL, Ashouri, JF, Matloubian, M, Cheng, DA, et al. A sharp T-cell antigen receptor signaling threshold for T-cell proliferation. Proc Natl Acad Sci USA 111 (2014), E3679–E3688.
42. 42 Peng, H, Sohara, Y, Moats, RA, Nelson, MD Jr, Groshen, SG, Ye, W, et al. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 67 (2007), 9346–9355.
43. 43 Bäckman, U, Svensson, A, Christofferson, RH, Azarbayjani, F, The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 28:3A (2008), 1551–1557.
44. 44 Gnant, M, Clézardin, P, Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 38 (2012), 407–415.
45. 45 Di Carlo, E, Bocca, P, Emionite, L, Cilli, M, Cipollone, G, Morandi, F, et al. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. Mol Ther 21 (2013), 1034–1043.
46. 46 Goto, H, Matsuda, K, Srikoon, P, Kariya, R, Hattori, S, Taura, M, et al. Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma. Cancer Lett 331 (2013), 174–182.
47. 47 Sprini, D, Di Stefano, L, Rini, GB, Cianferotti, L, Napoli, N, Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates. Clin Cases Miner Bone Metab 11 (2014), 126–128.
48. 48 Wada, I, Matsushita, H, Noji, S, Mori, K, Yamashita, H, Nomura, S, et al. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3 (2014), 362–375.
49. 49 Suzuki, T, Terao, S, Acharya, B, Naoe, M, Yamamoto, S, Okamura, H, et al. The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands. Anticancer Res 30 (2010), 4509–4513.
50. 50 Pardoll, DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
51. 51 Dudley, ME, Wunderlich, JR, Shelton, TE, Even, J, Rosenberg, SA, Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26 (2003), 332–342.
52. 52 Chien, YH, Meyer, C, Bonneville, M, γδ T cells: first line of defense and beyond. Annu Rev Immunol 32 (2014), 121–155.
53. 53 Gros, A, Robbins, PF, Yao, X, Li, YF, Turcotte, S, Tran, E, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124 (2014), 2246–2259.
54. 54 Downing, JR, Wilson, RK, Zhang, J, Mardis, ER, Pui, CH, Ding, L, et al. The Pediatric Cancer Genome Project. Nat Genet 44 (2012), 619–622.
55. 55 Robinson, G, Parker, M, Kranenburg, TA, Lu, C, Chen, X, Ding, L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488 (2012), 43–48.
56. 56 Zhang, J, Benavente, CA, McEvoy, J, Flores-Otero, J, Ding, L, Chen, X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481 (2012), 329–334.
57. 57 Zhang, J, Ding, L, Holmfeldt, L, Wu, G, Heatley, SL, Payne-Turner, D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481 (2012), 157–163.
58. 58 Barrett, AJ, Bollard, CM, The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. Ann Transl Med, 3, 2015, 62.
59. 59 Saglio, F, Hanley, PJ, Bollard, CM, The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16 (2014), 149–159.
60. 60 Vantourout, P, Hayday, A, Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol 13 (2013), 88–100.
61. 61 Lefranc, MP, Giudicelli, V, Ginestoux, C, Jabado-Michaloud, J, Folch, G, Bellahcene, F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37:Database issue (2009), D1006–D1012.
62. 62 Bell, J, A simple way to treat PCR products prior to sequencing using ExoSAP-IT. Biotechniques, 44, 2008, 834.
63. 63 Workman, CJ, Dugger, KJ, Vignali, DA, Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 169 (2002), 5392–5395.
64. 64 Persons, DA, Allay, JA, Allay, ER, Smeyne, RJ, Ashmun, RA, Sorrentino, BP, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90 (1997), 1777–1786.
65. 65 Heemskerk, MH, Hoogeboom, M, de Paus, RA, Kester, MG, van der Hoorn, MA, Goulmy, E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102 (2003), 3530–3540.